乳腺癌患者恶性肿瘤家族史的影响因素分析

Analysis of Influencing Factors of Family History of Malignant Tumor in Patients with Breast Cancer

目的分析乳腺癌患者恶性肿瘤家族史(familial history of malignant neoplasm,MN-FH)的影响因素。方法回顾性分析2019年7月—2021年7月期间枣庄市妇幼保健院收治的130例乳腺癌患者的临床资料,以是否存在乳腺癌家族史将患者分为存在MN-FH组(n=70)与未存在MN-FH组(n=60),并进行乳腺癌患者MN-FH的单因素和多因素Logistic分析。结果130例患者中70例患者存在MN-FH,占同期乳腺癌患者的53.85%。两组患者肿瘤直径、神经侵犯、血管血栓形成、淋巴结转移、Ki67、合并其他肿瘤、病理类型比较,差异无统计学意义(χ^(2)=0.331、0.177、0.004、0.147、0.564、1.173、1.020,P>0.05);乳腺癌临床病理分期、ER、PR、HER-2比较,差异有统计学意义(P<0.05)。多因素Logistic结果显示乳腺癌临床病理分期、ER、PR、EHR-2是MN-FH的危险因素(OR=2.674,3.242,2.016,2.103,P<0.05)。结论超过1/2的乳腺癌患者存在MN-FH。存在MNFH的乳腺癌患者肿瘤恶性程度更高,因此,针对有恶性肿瘤家族史的人群进行定期的体检极为重要,是早诊断、早治疗、提高患者生存率的关键。

Objective To analyze the influencing factors of family history of malignant tumor(MN-FH)in breast cancer patients.Methods The clinical data of 130 patients with breast cancer admitted to Zaozhuang Maternal and Child Health Hospital from July 2019 to July 2021 were retrospectively analyzed.The patients were divided into those with MN-FH(n=70)and those without MN-FH(n=60)based on whether there was a family history of breast cancer,single factor and multi factor logistic analysis of MN-FH in breast cancer patients was carried out.Results Among 130 patients,70 patients had MN-FH,accounting for 53.85%of breast cancer patients in the same period.There was no statistically significant difference in tumor diameter,nerve invasion,vascular thrombosis,lymph node metastasis,Ki67,other tumors and pathological types between the two groups(χ^(2)=0.331,0.177,0.004,0.147,0.564,1.173,1.020,P>0.05);there was statistically significant difference in clinicopathologic stage,ER,PR and HER-2(P<0.05).Multivariate logistic results showed that clinicopathological stage,ER,PR,EHR-2 were risk factors for MN-FH in breast cancer(OR=2.674,3.242,2.016,2.103,P<0.05).Conclusion More than 1/2 breast cancer patients in our hospital have MN-FH.Breast cancer patients with MN-FH have a higher degree of malignancy.Therefore,it is extremely important to conduct regular physical examinations for people with a family history of malignant tumors.It is the key to early diagnosis and early treatment to improve the survival rate of patients.